DLin-KC2-DMA

DLin-KC2-DMA is an ionizable cationic lipid (apparent pK_a = 6.7) that has been used in the formation of lipid nanoparticles (LNPs) encapsulating siRNA or plasmid DNA for use in vitro and in vivo.^1,2 LNPs containing DLin-KC2-DMA selectively accumulate in the liver after intravenous or intramuscular administration in mice or localize to the retinal pigment epithelium and Müller glia after subretinal administration.^2,3 DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting F7 mRNA, which encodes Factor VII, reduce serum Factor VII levels in mice.¹ Intravenous administration of DLin-KC2-DMA-containing LNPs encapsulating siRNA targeting AR mRNA, which encodes the androgen receptor, decrease serum prostate-specific antigen (PSA) and tumor androgen receptor levels in an LNCaP prostate cancer mouse xenograft model.⁴

WARNING This product is not for human or veterinary use.

1. Semple, S.C., Akinc, A., Chen, J., et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28(2), 172-176 (2010).

2. Algarni, A., Pilkington, E.H., Suys, E.J.A., et al. In vivo delivery of plasmid DNA by lipid nanoparticles: The influence of ionizable cationic lipids on organ-selective gene expression. Biomater. Sci. 10(11), 2940-2952 (2022).

3. Patel, S., Ryals, R.C., Weller, K.K., et al. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J. Control Release 303, 91-100 (2019).

4. Lee, J.B., Zhang, K., Tam, Y.Y.C., et al. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int. J. Cancer 131(5), E781-E790 (2012).